Drugs / LVT-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06821126 | May 2025 → Oct 2026 expected | — | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06821126 ↗ |
| Modality | Vaccine | “intranasal recombinant protein vaccine LVT-001” NCT06821126 ↗ |
| Route | Intranasal | “One booster dose of the intranasal vaccine LVT-001 administered as a nasal spray in each nostril at Day 0.” NCT06821126 ↗ |